Agenus (AGEN) vs Kyverna Therapeutics (KYTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Agenus (AGEN) has outperformed Kyverna Therapeutics (KYTX) over the past year, gaining 80.8% versus a loss of 13.9%. Kyverna Therapeutics is the larger company by market cap ($395.2 million vs $346.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AGEN | KYTX |
|---|---|---|
| Share price | $7.67 | $6.39 |
| Market cap | $346.39M | $395.18M |
| 1-day change | +1.72% | +3.40% |
| YTD return | +140.13% | -34.26% |
| 1-year return | +80.82% | -13.93% |
| 5-year return | -92.77% | — |
| P/E ratio (TTM) | 3.03 | — |
| EPS (TTM) | $2.53 | $-2.93 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $10.31 | $13.67 |
| 52-week low | $2.71 | $5.96 |
| Distance from 52-week high | -25.61% | -53.26% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +243.29% | +375.74% |
| Average volume | 4.26M | 903.83K |
| Shares outstanding | 45.16M | 61.84M |
| Employees | 81 | 149 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AGEN has outperformed KYTX by 94.7 percentage points over the past year.
About Agenus
AGEN stock →Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 81 employees
About Kyverna Therapeutics
KYTX stock →Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 149 employees
AGEN vs KYTX FAQ
Which is bigger, Agenus or Kyverna Therapeutics?
Kyverna Therapeutics (KYTX) is larger, with a market capitalization of $395.18M compared with $346.39M for Agenus (AGEN).
Which stock has performed better over the past year, AGEN or KYTX?
AGEN returned +80.82% over the past 12 months, compared with -13.93% for KYTX (price return, excluding dividends). Past performance does not predict future results.
Are Agenus and Kyverna Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.